Skip to main
BFRI
BFRI logo

Biofrontera (BFRI) Stock Forecast & Price Target

Biofrontera (BFRI) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biofrontera Inc is positioned for significant revenue growth due to the anticipated market launches of new indications for treating superficial Basal Cell Carcinoma and Actinic Keratoses, projected for 2026 and 2027. The company stands to benefit from an increase in sales personnel and favorable reimbursement policies, enhancing the competitive edge of its flagship product, Ameluz, over cryotherapy and attracting new customers to photodynamic therapy. Additionally, historical sales trends indicate that the fourth quarter, bolstered by increased dosage options for Ameluz, will likely be crucial for driving revenue growth this year.

Bears say

Biofrontera Inc. is facing a negative outlook primarily due to its revenue performance, which for the period amounted to $8.6 million, significantly below both the company's and consensus estimates of $10.6 million. This revenue shortfall raises concerns about the company's ability to execute on its growth strategy, as reflected in the downward adjustment of its price target from $7 to $2.75 per share based on comparative group averages. Additionally, potential regulatory surprises could further hinder revenue generation and escalate operational costs, compounding the challenges the company currently faces.

Biofrontera (BFRI) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biofrontera (BFRI) Forecast

Analysts have given Biofrontera (BFRI) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Biofrontera (BFRI) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biofrontera (BFRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.